We are dedicated to developing the next generation of target
protein degrader (TPD) and kinase inhibitors that could be much
safer and more efficacious oncology medicines that transform
patient’s lives.
We have a
CHANDEL (
CHAapero
Ne Mediated
DEgrader p
Latform) platform technology to evaluate chaperon mediated
degradable molecular targets and fast-paced drug discovery
development.
Through this focus, we developed in first-in-class orally
available mtPI3K chaperon degrader that harness body’s
natural chaperon system to rapidly degrade disease causing proteins
and did not cause dose limited toxicity issue, facing with approved
PI3K drugs such as alpelisib and inavolisib.